PhRMA adds 5 member companies
WASHINGTON — The Pharmaceutical Research and Manufacturers of America on Friday announced that it had added five new companies to its membership roster. Three of the companies joined as members and two transitioned from research associates to full members.
New members are Alexion Pharmaceuticals and Jazz Pharmaceuticals, and Teva, AMAG Pharmaceuticals and Horizon Pharma made the transition to full members.
“On behalf of the PhRMA Board of Directors, I am proud to welcome these companies into our membership,” PhRMA chairman and Biogen CEO George A. Scangos said. “Together as an industry, we can continue our work on issues to advance biomedical innovation and improve patient care.”
These companies join PhRMA’s efforts to advocate for policy solutions focused on innovative treatments through drug discovery and development, promoting value-driven health care, engaging and empowering consumers and addressing market distortions.
“We are pleased to welcome these companies into our membership. Collectively, our members are at the forefront of the most exciting and innovative biopharmaceutical research taking place in the industry today,” PhRMA president and CEO Stephen Ubl said. “The addition of these biopharmaceutical research companies will help guide us as we advocate for patient-centric policies to enhance the private market and address costs holistically.”
Pharmacy automation market to hit $7.8B by 2018
ALBANY, N.Y. — New research from Transparency Market Research is taking a look at the market size of the global pharmacy automation systems market, highlighting big growth ahead in the next several years. TMR projects that the market will hit $7.8 billion in 2018, up from the $4.7 billion that the market was valued at in 2011. And a big driver of growth comes from automated dispensing systems.
Based on TMR’s research, about 48% of the overall market and generated revenue — about $2.3 billion — can be attributed to automated medication dispensing systems, and this segment is expected to see a compound annual growth rate (CAGR) of 6.7% by 2020, when it will be worth $3.6 billion.
“The pressing need to prevent medical prescription errors has stoked the demand for automated medication dispensing systems,” a TMR analyst said. "Dispensing the right dosage of medicine and reviewing the inventory at a specified location help to increase the efficiency of a pharmacy while keeping the costs low.”
TMR pointed out that the high cost of implementation has been and will continue to be a barrier to growth, even as the growth of e-prescribing (particularly in Europe and North America has fueled demand). Despite the barrier of upstart cost, though, the analysis projects a CAGR of 7.3% between 2012 and 2018.
BioPlus now dispensing Gilead’s Epclusa
ALTAMONTE SPRINGS, Fla. — BioPlus Specialty Pharmacy announced this week that it is now dispensing Gilead’s recently approved Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg).
The drug, which combines Gilead’s Sovaldi (sofosbuvir) with an NS5A inhibitor called velpatasvir, is indicated to treat all six strains of hepatitis C.
“One of the exciting things for prescribers and patients about Epclusa is that it’s approved to treat all six genotypes,” BioPlus VP pharmaceutical relations Sharon Ferrer said. “In addition, the low cost (wholesale acquisition cost of $74,760) comes in at nearly 50% lower than previous treatments available for the difficult-to-treat genotype 3 of hepatitis C virus.”
Loading Post Please Wait...